Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has gained significant attention in metabolic research. Marketed under brand names Mounjaro and Zepbound, tirzepatide is administered as a once-weekly subcutaneous injection. For researchers working with compounded tirzepatide vials rather than pre-filled manufacturer pens, accurate dose calculation and reconstitution math become essential — and the process is different enough from standard peptide protocols to warrant its own guide.
This article walks through the standard tirzepatide titration schedule, how to calculate doses from compounded vials using an insulin syringe, injection technique, missed dose protocols, and practical considerations around food timing.
Understanding the Tirzepatide Titration Schedule
Tirzepatide uses a slow, stepwise titration schedule designed to minimize gastrointestinal side effects — primarily nausea, which is the most commonly reported adverse event in clinical trials. The standard protocol increases the dose every four weeks, giving the body time to adjust at each level.
| Step | Weekly Dose | Duration | Notes |
|---|---|---|---|
| 1 | 2.5 mg | 4 weeks | Starting dose — primarily for GI adjustment |
| 2 | 5 mg | 4 weeks | First therapeutic dose level |
| 3 | 7.5 mg | 4 weeks | Intermediate step; some protocols stay here |
| 4 | 10 mg | 4 weeks | Common maintenance dose |
| 5 | 12.5 mg | 4 weeks | Higher tier; assess tolerability before advancing |
| 6 | 15 mg | Ongoing | Maximum studied dose |
Each dose increase is separated by a minimum of four weeks. Advancing too quickly is the most common reason for severe nausea and vomiting. If side effects are significant at any step, most protocol guides recommend staying at the current dose for an additional 4 weeks before attempting to increase. There is no requirement to reach 15mg — many protocols stabilize at 5mg, 7.5mg, or 10mg based on individual response.
If you're familiar with semaglutide titration, the framework is similar but the dose steps and compound mechanism differ. Our semaglutide titration schedule guide provides a useful comparison point.
Reconstitution Math for Compounded Tirzepatide Vials
Pre-filled manufacturer pens (Mounjaro/Zepbound) come pre-dosed and require no calculation. However, compounded tirzepatide arrives as lyophilized powder in vials, and you must reconstitute it yourself and calculate the correct injection volume for your target dose.
The key variables are:
- Total peptide in the vial (e.g., 30mg, 50mg, or 60mg)
- Volume of bacteriostatic water (BAC water) added
- Your target weekly dose (e.g., 2.5mg, 5mg, 10mg)
Step-by-Step Reconstitution Calculation
The formula is straightforward:
Then to find the injection volume for your dose:
Here is a practical example using a common vial size:
| Vial Size | BAC Water | Concentration | 2.5mg Dose | 5mg Dose | 10mg Dose |
|---|---|---|---|---|---|
| 30 mg | 3 mL | 10 mg/mL | 0.25 mL (25 units) | 0.50 mL (50 units) | 1.00 mL (100 units) |
| 30 mg | 2 mL | 15 mg/mL | 0.167 mL (17 units) | 0.333 mL (33 units) | 0.667 mL (67 units) |
| 60 mg | 3 mL | 20 mg/mL | 0.125 mL (13 units) | 0.25 mL (25 units) | 0.50 mL (50 units) |
| 60 mg | 6 mL | 10 mg/mL | 0.25 mL (25 units) | 0.50 mL (50 units) | 1.00 mL (100 units) |
On a standard U-100 insulin syringe, 1 mL = 100 units. So 0.25 mL = 25 units, 0.50 mL = 50 units, and so on. When dealing with fractional units (like 17 units or 33 units), round to the nearest whole unit marking on your syringe. For more precise calculations, use our reconstitution calculator — enter your vial size, water volume, and target dose to get the exact injection volume.
For a deeper walkthrough of reconstitution technique and best practices, see our peptide reconstitution guide.
Reading an Insulin Syringe for Tirzepatide Doses
Compounded tirzepatide is drawn using standard insulin syringes (typically U-100). Understanding how to read the markings correctly is critical for accurate dosing.
| Syringe Size | Graduation Marks | Best For |
|---|---|---|
| 0.3 mL (30 units) | Every 0.5 units | Low doses (2.5mg-5mg from concentrated solutions) |
| 0.5 mL (50 units) | Every 1 unit | Mid-range doses; good general-purpose option |
| 1.0 mL (100 units) | Every 2 units | Higher doses or less concentrated solutions |
Always use the smallest syringe that accommodates your injection volume. Smaller syringes have finer graduation marks, which allows for more accurate measurement of your calculated dose.
Injection Technique for Tirzepatide
Tirzepatide is administered as a subcutaneous injection, meaning it goes into the fat layer just beneath the skin — not into muscle. The recommended injection sites are:
- Abdomen: At least 2 inches from the navel, avoiding the waistline area
- Front of thighs: Upper outer area, midway between the knee and hip
- Upper arm: Back of the upper arm (easier with assistance)
Rotate injection sites each week to prevent lipodystrophy (hardening or dimpling of the skin from repeated injections in the same spot). A simple rotation system — left abdomen, right abdomen, left thigh, right thigh — ensures you cycle through sites evenly.
Injection Steps
- Clean the injection site with an alcohol swab and allow it to dry
- Pinch a fold of skin at the injection site
- Insert the needle at a 45-90 degree angle (90 degrees for areas with adequate subcutaneous fat)
- Inject slowly and steadily
- Hold the needle in place for 5-10 seconds after the plunger is fully depressed
- Release the skin fold and withdraw the needle
- Do not rub the injection site
Missed Dose Protocol
Because tirzepatide is dosed weekly, missed doses are handled differently than daily peptide injections:
- Less than 4 days late (96 hours): Take the missed dose as soon as possible, then resume your regular schedule on your usual day
- More than 4 days late: Skip the missed dose entirely and take your next scheduled dose on your regular injection day
- Never double up: Do not take two doses in the same week to make up for a missed injection
Consistency matters with weekly injections. Choosing the same day and approximate time each week — and logging it — significantly reduces the chance of missed doses.
Food and Timing Considerations
Tirzepatide can be injected at any time of day, with or without food. However, there are practical timing considerations worth noting:
- Nausea management: Some protocols recommend injecting after a light meal or in the evening before bed, so that any initial nausea occurs during sleep
- Meal planning: Tirzepatide significantly slows gastric emptying. Eating large, high-fat meals may increase nausea and bloating. Smaller, more frequent meals are commonly recommended during titration
- Alcohol: Research suggests caution with alcohol while on tirzepatide, as the combination may increase the risk of hypoglycemia and worsen GI side effects
- Hydration: Adequate water intake is emphasized in most protocols, as GI side effects can contribute to dehydration if nausea or diarrhea occurs
Side Effects by Titration Step
Understanding which side effects are most common at each stage helps set expectations:
| Dose | Common Side Effects | Management |
|---|---|---|
| 2.5 mg | Mild nausea, reduced appetite | Usually resolves within 1-2 weeks |
| 5 mg | Nausea, diarrhea, constipation | Smaller meals, adequate hydration |
| 7.5-10 mg | GI symptoms may recur at each step-up | Extend step to 6-8 weeks if needed |
| 12.5-15 mg | Fatigue, injection site reactions, hair thinning (rare) | Assess if the higher dose is necessary |
Frequently Asked Questions
How does tirzepatide differ from semaglutide in terms of dosing?
Both are once-weekly subcutaneous injections with titration schedules, but tirzepatide targets two receptors (GIP and GLP-1) while semaglutide targets only GLP-1. Tirzepatide's dose range (2.5mg-15mg) is higher in absolute milligrams than semaglutide's (0.25mg-2.4mg) because the two compounds have different potencies per milligram. The titration philosophy is the same: start low and increase every 4 weeks as tolerated.
Can I add more BAC water to my vial if my injection volume is too small to measure accurately?
Yes. Adding more bacteriostatic water creates a less concentrated solution, which increases the injection volume per dose and makes it easier to measure on your syringe. For example, if your current concentration yields a 5-unit injection for your dose, adding more water to double the volume to 10 units makes it easier to draw accurately. Just recalculate your concentration after adding water. The reconstitution calculator can help you determine the right water volume for your preferred injection volume.
What happens if I experience severe nausea after increasing my dose?
If nausea is severe or persistent after a dose increase, most protocol guides recommend dropping back to the previous tolerated dose for an additional 4 weeks before reattempting the increase. Pushing through severe nausea is not recommended, as it can lead to dehydration and makes compliance difficult. Some protocols also suggest splitting the dose increase — for example, going from 5mg to 6.25mg (if your concentration allows it) rather than jumping straight to 7.5mg.
How should compounded tirzepatide vials be stored after reconstitution?
After reconstitution with bacteriostatic water, tirzepatide vials should be refrigerated at 36-46°F (2-8°C). Most compounding sources recommend using the reconstituted solution within 28 days. Do not freeze reconstituted tirzepatide, and avoid leaving it at room temperature for extended periods. Always inspect the solution before drawing — it should be clear and colorless with no visible particles.
Sources and References
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022 (SURMOUNT-1).
- Frias JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." N Engl J Med. 2021 (SURPASS-2).
- FDA: Mounjaro (tirzepatide) Prescribing Information
- Coskun T, et al. "LY3298176, a novel dual GIP and GLP-1 receptor agonist: preclinical pharmacology and clinical development." Mol Metab. 2018.
- FDA: Zepbound (tirzepatide) Prescribing Information